Allakos Inc (ALLK) - Total Liabilities
Based on the latest financial reports, Allakos Inc (ALLK) has total liabilities worth $4.08 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ALLK cash generation efficiency to assess how effectively this company generates cash.
Allakos Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Allakos Inc's total liabilities have evolved over time, based on quarterly financial data. Check Allakos Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Allakos Inc Competitors by Total Liabilities
The table below lists competitors of Allakos Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KPX Lifescience.Co.Ltd
KQ:114450
|
Korea | ₩15.22 Billion |
|
J.ESTINA Co.Ltd
KQ:026040
|
Korea | ₩9.85 Billion |
|
Ledlink Optics
TWO:5230
|
Taiwan | NT$1.02 Billion |
|
Bakrie Sumatera Plantations
JK:UNSP
|
Indonesia | Rp8.59 Trillion |
|
Nova MSC Bhd
KLSE:0026
|
Malaysia | RM20.24 Million |
|
Numulae Gestion de Servicios SOCIMI SA
MC:YNUM
|
Spain | €21.51 Million |
|
Bioceres Crop Solutions Corp
NASDAQ:BIOX
|
USA | $455.83 Million |
|
Foxx Development Holdings Inc.
NASDAQ:FOXX
|
USA | $53.87 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Allakos Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ALLK company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Allakos Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Allakos Inc (2016–2024)
The table below shows the annual total liabilities of Allakos Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $17.78 Million | -76.22% |
| 2023-12-31 | $74.79 Million | -1.57% |
| 2022-12-31 | $75.99 Million | -14.95% |
| 2021-12-31 | $89.35 Million | +36.99% |
| 2020-12-31 | $65.22 Million | +208.05% |
| 2019-12-31 | $21.17 Million | +191.44% |
| 2018-12-31 | $7.26 Million | -95.02% |
| 2017-12-31 | $145.80 Million | +188.07% |
| 2016-12-31 | $50.61 Million | -- |
About Allakos Inc
As of May 15, 2025, operates as a subsidiary of Concentra Biosciences, LLC.